Targeting a specific molecule toward transporters by designing its prodrugs may be used to improve oral bioavailability or to reduce systemic toxicity. [1] [2] [3] [4] [5] [6] Valine prodrugs of acyclovir and ganciclovir, valacyclovir and valganciclovir, respectively, exhibit 3-5 times higher systemic exposure than the parent compounds. [7] [8] [9] Enhanced bioavailabilities of the amino acid prodrugs is attributed to carrier mediated intestinal absorption via intestinal transporters such as a human peptide transporter hPept1 or an amino acid transporter ATB 0,ϩ . 4, [10] [11] [12] Nucleoside antiviral and anticancer agents are important class of drugs for the fight against viral diseases and cancer. However, they often exhibit poor pharmaceutical and absorption, distribution, metabolism and excretion (ADME) properties. Prodrug approaches that can potentially improve their pharmaceutical and ADME properties can be of great benefit in realizing the full potential of these agents.
Targeting a specific molecule toward transporters by designing its prodrugs may be used to improve oral bioavailability or to reduce systemic toxicity. [1] [2] [3] [4] [5] [6] Valine prodrugs of acyclovir and ganciclovir, valacyclovir and valganciclovir, respectively, exhibit 3-5 times higher systemic exposure than the parent compounds. [7] [8] [9] Enhanced bioavailabilities of the amino acid prodrugs is attributed to carrier mediated intestinal absorption via intestinal transporters such as a human peptide transporter hPept1 or an amino acid transporter ATB 0,ϩ . 4, [10] [11] [12] Nucleoside antiviral and anticancer agents are important class of drugs for the fight against viral diseases and cancer. However, they often exhibit poor pharmaceutical and absorption, distribution, metabolism and excretion (ADME) properties. Prodrug approaches that can potentially improve their pharmaceutical and ADME properties can be of great benefit in realizing the full potential of these agents.
Clinically important nucleoside drugs such as cladribine, dideoxyinosine, fludarabine, acyclovir, ganciclovir, and abacavir, gemcitabine, azidothymidine, FUdR, cytarabine, zalcitabine and stavudine are known to interact with nucleoside transporters, which can influence their ADME properties. [13] [14] [15] A sodium-dependent concentrative nucleoside transporter hCNT2 has been cloned from human intestine. [16] [17] [18] The hCNT2 is abundantly expressed in the intestinal tissues, and is involved in transport of both naturally occurring nucleosides and clinically relevant nucleoside analogs. 13, 18) Of the subtypes of concentrative nucleoside transporter hCNT1-3, hCNT2 exhibits a preference for purine nucleosides over pyrimidine nucleosides. 13, 19) FUdR is a fluorinated pyrimidine nucleoside drug extensively used in the treatment of colon cancer. Although the mechanism of action and therapeutic effectiveness of FUdR are well understood, it has various side effects in gastrointestinal and bone marrow tissues. 20) Hence, FUdR is administered parenterally due to its poor oral bioavailability. Recently, benzimidazole nucleosides such as BDCRB, maribavir, and GW275175X have also been developed as a new class of antiviral drugs. [21] [22] [23] Although BDCRB was found to be a potent and selective inhibitor of human cytomegavirus (HCMV) replication, it had a poor pharmacokinetics profile with a very short plasma half-life and cytotoxicity. 24, 25) In this regard, we attempted to develop amino acid ester prodrugs of FUdR and BDCRB to improve their pharmacokinetic properties. Although considerable progress has been made in the development of amino acid or dipeptide nucleoside prodrugs, little is known about the nucleoside transporters involved in the intestinal absorption of the prodrugs. In a previous report, 18) we demonstrated that FUdR and BDCRB were potent inhibitors of intestinal nucleoside transporter hCNT2. This suggests that hCNT2 may play an important role in the uptake of nucleoside compounds from the intestine. Therefore, it is relevant to characterize how the attachment of amino acids to the nucleoside derivatives FUdR and BDCRB influences their binding affinity for hCNT2 transporter. In the present study, we examined the interaction of hCNT2 cloned from human duodenum with amino acid ester prodrugs of FUdR and BDCRB to investigate the effect of amino acid esterification on the uptake activity of an intestinal nucleoside transporter hCNT2. Prodrug Synthesis Amino acid ester prodrugs of FUdR and BDCRB were synthesized as described previously. 3, 26) Aromatic amino acids L-Phe and D-Phe, aliphatic amino acids L-Val and D-Val, secondary amino acid Pro, acidic amino acid Asp, and basic amino acid Lys were selected as promoieties for the synthesis of FUdR prodrugs. Phe, L-Val, D-Val, Pro, Asp, and Lys were selected for the synthesis of BDCRB prodrugs. The purity of prodrugs was determined by HPLC (Waters). Electrospray ionization mass spectra (ESI-MS) were obtained on a Thermo-quest LCQ electrospray ionization mass spectrometer. Proton nuclear magnetic resonance spectra ( 1 H-NMR) were obtained on a 300-MHz Bruker DPX-300 NMR spectrometer.
Interaction of Intestinal
Cloning of hCNT2 The nucleoside transporter cDNA was obtained from human intestine by reverse transcriptase polymerase chain reaction (RT-PCR). The first strand cDNA was synthesized from total RNA using the SuperScript Choice System (Gibco BRL) and T7-(dT) 24 oligomer. PCR amplification was performed using two primers 5Ј-GGA-GAACAGGAGATGGAGAAA-3Ј and 5Ј-TAGATCAAGCA-GCCTTAGGCAC-3Ј. PCR was performed under the following conditions: 1 cycle at 95°C for 2 min, 30 cycles at 95°C for 30 s, 55°C for 30 s, 72°C for 4 min 30 s, and one final cycle at 72°C for 10 min (GeneAmp ® PCR System 9700, Applied Biosystems, Foster City, CA, U.S.A.). The PCR product was cloned into the vector Zero Blunt ® TOPO (Invitrogen). Positive clone was confirmed by restriction analysis with enzyme EcoRI, followed by DNA sequencing with M13-reverse and -forward (Ϫ20) sequencing primers (DNA Sequencing Core, The University of Michigan). The TOPOhCNT2 plasmid was digested with XhoI and BamHI enzymes. The digested hCNT2 cDNA was subcloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen) to form the pcDNA3.1/hCNT2 construct. T4 DNA Ligase (New England Biolabs) was used to ligate the XhoI/BamHI sites.
Cell Culture and Transient Transfection of hCNT2 in U251 Cells U251 cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum. All cells were cultured in an atmosphere of 5% CO 2 and 90% relative humidity at 37°C. One day before transfection, U251 cells were trypsinized and plated onto 12-well plates at a density of approximately 2.5ϫ10 5 cells/well. Transfection mixture was prepared by adding 0.5 mg of pcDNA3.1/hCNT2 plasmid and 1.5 ml of transfection reagent FuGENE-6 to 0.1 ml of serum free RPMI 1640 and allowed to incubate for 45 min at room temperature. To each well, 0.1 ml of transfection mixture was added and cells were incubated for 48 h at 37°C in a 5% CO 2 ]-adenosine (25 nM radiolabeled compounds plus 1 mM unlabeled compounds) was added to each well and incubated for 5 min at room temperature on a low-speed rotator. All uptake studies were carried out in the presence of 10 mM NBMPR. Sodium dependent or independent uptake was measured in the presence or absence of sodium in the 5 mM Hepes/Triss buffer. The transport was stopped by aspirating the reaction mixture and washing cells three times with icecold sodium free buffer. Cells were then solubilized in 1 ml of 1% SDS. The tritium content of the cell lysate (0. 3 H]-adenosine uptake by hCNT2 transfected cells was carried out in the presence of 1000 mM FUdR, BDCRB, and their amino acid prodrugs. All inhibition studies were carried out in the presence and absence of sodium. Data Analysis All uptake data are expressed as meanϮ S.D. Statistical significance was determined using Student's t-test and a pϽ0.05 was considered statistically significant.
RESULTS
Amino acid ester prodrugs of FUdR and BDCRB were successfully synthesized as described previously (Fig. 1) . 3, 26) The purity of all prodrugs was more than 90% as determined by HPLC. The impurities were generally the known amino acid ester prodrugs or the parent drug. The identity of the prodrugs was confirmed by electrospray ionization-mass spectrometry (ESI-MS) and proton nuclear magnetic resonance ( 1 H-NMR). All prodrugs resulted in correct molecular weight and expected 1 H-NMR. The hCNT2 cDNA cloned from human duodenum had the same predicted amino acid sequence as the 658-residue hCNT2 protein reported from human intestine (GenBank accession number U84392). The stably transfected U251/hCNT2 expression system represented a very useful tool for rapid transport screening of the synthesized amino acid prodrugs. 18) Adenosine and inosine are substrates of hCNT2 transporter. 18) Interaction of amino acid ester prodrugs of FUdR with the cloned intestinal hCNT2 was assessed by determin-ing the influence of these prodrugs on the transport of native nucleosides, adenosine and inosine. Interaction of amino acid ester prodrugs of BDCRB with hCNT2 was assessed by determining the influence of these prodrugs on the uptake of adenosine and inosine. As shown in Figs. 4 
DISCUSSION
Prodrug strategy is a very attractive approach to improve the biopharmaceutical properties and safety of clinically important nucleoside antiviral and anticancer agents. 3, 27) Most nucleoside analogs contain free hydroxyl groups which can be easily esterified to obtain ester prodrugs. Although alkyl ester prodrugs are commonly utilized, the use of amino acids as promoieties offers several advantages: structural diversity, well established peptide chemistry, and potential targetability to carrier-mediated membrane transporters. 3, 27) In this regard, the use of intestinal epithelial transporters to facilitate the absorption of amino acid prodrugs of antiviral and antitumoral nucleoside agents is a very viable approach to increase their oral bioavailability.
The pyrimidine nucleoside FUdR and the benzimidazole nucleoside BDCRB are potent anticancer and antiviral agents, respectively, but suffer from poor biopharmaceutical properties. 20, 24, 25) In an effort to improve the biopharmaceutical properties of FUdR and BDCRB, their amino acid ester prodrugs were synthesized and tested for interaction with intestinal epithelial transporters. Based on the site(s) of attachment of the promoiety, three types of FUdR prodrugs including 3Ј-monoesters, 5Ј-monoesters, and 3Ј,5Ј-diesters, and one type of BDCRB prodrug including 5Ј-monoesters were synthesized. These prodrugs were found to interact with the oligopeptide transporter hPEPT1. 26) Our earlier report demonstrated that FUdR and BDCRB exhibit high affinity for the intestinal hCNT2 transporter.
18) The nucleoside trans- porter hCNT2 transports native nucleosides such as adenosine, inosine, and uridine and the nucleoside drugs didanosine and ribavirin. Previous investigators have demonstrated that hCNT2 is abundantly expressed in human small intestine. 16, 18, 28) This suggests that hCNT2 may play an important role in the uptake of nucleoside compounds from the intestine. Therefore, it is relevant to characterize how the attachment of amino acids to the nucleoside derivatives FUdR and BDCRB influences their binding affinity for hCNT2 transporter.
Interaction of various amino acid prodrugs with hCNT2 was studied using the U251/hCNT2 expression system (Figs.  2-5 . These results demonstrate that modifications to BDCRB are well tolerated by hCNT2. It has been well documented that hCNT2 favorably interacts with purine over pyrimidine nucleosides, and favorably interacts with uridine analogs among pyrimidine nucleosides. The significant difference in hCNT2 binding affinity between the FUdR and BDCRB prodrugs may be due to distinct hCNT2 binding characteristics for FUdR and BDCRB. The binding pocket of FUdR, a pyrimidine nucleoside, is probably smaller and more selective, thus not allowing any modifications. The binding pocket of BDCRB, a purine nucleoside analog, is probably bigger and less selective, thus allowing additional modifications.
Recently, Chang et al. proposed that the binding site of hCNT1 transporter is rich in amino acids with strong hydrogen bond acceptor features. 30) Conversely, the active inhibitors of hCNT2 feature multiple hydrogen bond donor groups. Amino acid prodrugs of BDCRB contain an additional amino group, which can aid in their binding to hCNT2 transporter. Further, the neutral amino acid prodrugs of BDCRB, i.e., Val, D-Val, Phe, and Pro exhibited higher affinity for hCNT2 transporter than their hydrophilic counterparts, i.e., Asp and Lys. This indicates that either hCNT2 transporter favors hydrophobic over hydrophilic amino acids or that the hydrogen bond acceptor and donor side chains of Asp and Lys, respectively, interact unfavorably with the hCNT2 binding site. Although the transport of BDCBR and its prodrugs by hCNT2 transporter needs to be evaluated because the inhibitory effect may not correspond to the transport activity, this is the first report where amino acid ester prodrugs of nucleoside agents were shown to bind hCNT2 transporter. Hence, it may be suggested that intestinal hCNT2 may play an important role in the oral pharmacokinetics of amino acid prodrugs of BDCRB together with parent compound BDCRB. The stereochemistry and site of esterification of the amino acid promoiety can affect the properties of prodrugs. 3, 31, 32) However, in this study, there was no significant difference in the uptake of both [ 3 H]-inosine and [ 3 H]-adenosine between 3Ј-and 5Ј-monoester prodrugs or between L-and D-amino acid prodrugs, respectively. This means that amino acid stereochemistry and site of esterification had no significant effect on hCNT2 affinity.
In conclusion, we found that (1) FUdR and BDCRB have high affinity for hCNT2 transporter, (2) attachment of an amino acid to FUdR significantly decreases its affinity for hCNT2 transporter, (3) hCNT2 favorably interacts with both BDCRB and its amino acid prodrugs compared to those of FUdR, and (4) hCNT2 exihibits higher affinities for hydrophobic than hydrophilic amino acid prodrugs of BDCRB. This opens a new direction for the design of amino acid prodrugs of antiviral and antitumoral nucleoside agents and for drug related transporter targeting for effective intestinal delivery.
